pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
OPDIVO QVANTIG · news · pharmadog
← back to OPDIVO QVANTIG
News mentioning OPDIVO QVANTIG
60
stories
15h
Merck scraps centerpiece of $2.7B ArQule buy after late-stage safety concerns
biospace
2d
Sellas marks 9-month survival benefit in late-stage leukemia vaccine study
fiercebiotech
6d
BMS R&D head to depart amid restructure
biospace
8d
Bayer wins first-in-class FDA nod for blood thinner, setting stage for BMS-J&J rival
biospace
20d
BMS drops Prothena-partnered neuro drug, sales outlook improves on a Q3 beat
biospace
23d
ESMO 2026: Analysts warm to Merck, Moderna’s cancer vaccine after frustrating data leak
biospace
Oct 14, 26
J&J’s disappointing Q3, RevMed’s subgroup data, BMS’ ‘mixed’ results, Caribou’s cutback
biospace
Oct 12, 26
BMS’ Phase 3 win for lung drug clouded by high-dose miss
biospace
Oct 12, 26
BMS doubles up with pivotal wins in lung disease, solid tumor that offer hope for post-patent cliff growth
fiercebiotech
Oct 8, 26
Ono pays $80M for regional rights to trio of Biohaven IgG degraders, including phase 3 Grave’s asset
fiercebiotech
Oct 8, 26
Q3 layoffs down YOY, with 90% fewer biopharma employees affected
biospace
Oct 7, 26
Halozyme prevails in patent fight with Merck; Enliven readies anticipated leukemia trial
biopharma dive
Oct 5, 26
Significant stock movers of September: Viking soars, Longeveron slides
biospace
Oct 2, 26
BMO most bullish on Merck's, bearish on BMS’ plans to contend with patent cliffs
biospace
Sep 14, 26
Unlocking cell surface protein research with site-specific labeling
biospace
Sep 14, 26
5 drugmakers chasing Merck and Moderna in the cancer vaccine race
biospace
Sep 9, 26
A new immuno-oncology play raises $225M for a next-generation drug
biopharma dive
Sep 3, 26
Akeso, Summit cancer drug confirms lung cancer survival benefit
biopharma dive
Sep 3, 26
Replimune’s melanoma drug would have been rejected again if not for senior CBER official
biospace
Sep 2, 26
Stripped of AstraZeneca safety net, BMS could face ‘carnage’ if high-risk clinical trial fails
biospace
Aug 24, 26
Capricor, Replimune reviews signal FDA’s return to reliability but every application will stand alone
biospace
Aug 17, 26
AstraZeneca scraps Phase 3 trial of new bispecific in lung cancer
biopharma dive
Aug 10, 26
BMS picks Texas for new $2.3B manufacturing campus
biospace
Aug 6, 26
Replimune rebounds to win FDA approval of melanoma drug
biopharma dive
Aug 6, 26
Third time’s the charm for Replimune as melanoma drug earns FDA greenlight
biospace
Aug 6, 26
FDA Approves New Engineered Viral Immunotherapy for Patients with Treatment-Resistant Advanced Melanoma
fda press
Aug 5, 26
No deal between AstraZeneca and BMS, senior source insists: Reuters
biospace
Aug 5, 26
Chaotic adcomms threaten to derail FDA’s bid to renew trust after Makary, Prasad
biospace
Aug 5, 26
Rumors of biggest pharma merger ever drop amid Q2 earnings, contentious FDA adcomms
biospace
Aug 4, 26
As portfolio erodes, BMS stands to gain a lot from rumored AstraZeneca merger
biospace
← prev
page 1 of 2
next →